These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 34621642)

  • 1. Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.
    Yoon JH; Hong AR; Choi W; Park JY; Kim HK; Kang HC
    Chonnam Med J; 2021 Sep; 57(3):211-218. PubMed ID: 34621642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.
    Lee J; Cho YK; Kim HS; Jung CH; Park JY; Lee WJ
    Diabetes Metab Syndr Obes; 2019; 12():2745-2753. PubMed ID: 31920354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
    Ishii H; Onishi Y; Oura T; Takeuchi M
    Diabetes Ther; 2020 Jan; 11(1):133-145. PubMed ID: 31758520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
    Onishi Y; Ishii H; Oura T; Takeuchi M
    Diabetes Ther; 2020 Mar; 11(3):735-745. PubMed ID: 31994009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
    Patel H; Munir K; Sutherland S; Karanikas CA; Konig M
    Diabetes Ther; 2019 Dec; 10(6):2321-2330. PubMed ID: 31605302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study.
    Yoo JH; Cho YK; Lee J; Kim HS; Kang YM; Jung CH; Park JY; Lee WJ
    Diabetes Ther; 2019 Aug; 10(4):1453-1463. PubMed ID: 31240562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
    Yu M; Yuan GY; Zhang B; Wu HY; Lv XF
    Diabetes Ther; 2020 May; 11(5):1147-1159. PubMed ID: 32277401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
    Li Y; Li L; De Peng Y; Song GY; Ye SD; Du LY; Hou JN; Ji QH
    Diabetes Ther; 2019 Aug; 10(4):1435-1452. PubMed ID: 31228090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India.
    Wasir JS; Mithal A; Agarwal P; Mittal A
    Indian J Endocrinol Metab; 2018; 22(6):728-734. PubMed ID: 30766809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).
    Brož J; Janíčková Ždárská D; Štěpánová R; Kvapil M
    Diabetes Ther; 2019 Apr; 10(2):663-672. PubMed ID: 30788806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.
    Zang L; Han Y; Chen L; Hu D; Jin H; Yang N; Shi X; Liang L; Liu M; Fan H; Li Q; Mu Y
    Diabetes Ther; 2019 Aug; 10(4):1391-1405. PubMed ID: 31222594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
    Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
    Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review.
    Robinson S; Boye KS; Mody R; Strizek AA; Konig M; Malik RE; Kennedy-Martin T
    Diabetes Ther; 2020 Jul; 11(7):1437-1466. PubMed ID: 32524494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with Type 2 Diabetes: An Australian Single-Site Retrospective Chart Review.
    Houssarini JA; Brnabic AJM; Obaid M
    Diabetes Ther; 2022 Jan; 13(1):131-144. PubMed ID: 34850355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.
    Ma J; Zhang B; Hou J; Peng Y
    Diabetes Ther; 2021 Jan; 12(1):211-222. PubMed ID: 33161492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.